Comparative Pharmacology
Head-to-head clinical analysis: NUTRACORT versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTRACORT versus POKONZA.
NUTRACORT vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
One capsule (200 mg) orally twice daily with meals.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid